Published in Hypertension on February 27, 2012
Association of Uric Acid With Vascular Stiffness in the Framingham Heart Study. Am J Hypertens (2014) 1.48
Effects of long-term averaging of quantitative blood pressure traits on the detection of genetic associations. Am J Hum Genet (2014) 1.06
Arterial stiffness and hypertension. Hypertension (2014) 1.05
High pulsatility flow stimulates smooth muscle cell hypertrophy and contractile protein expression. Am J Physiol Lung Cell Mol Physiol (2012) 1.00
Stiffening-induced high pulsatility flow activates endothelial inflammation via a TLR2/NF-κB pathway. PLoS One (2014) 0.88
High Pulsatility Flow Induces Acute Endothelial Inflammation through Overpolarizing Cells to Activate NF-κB. Cardiovasc Eng Technol (2013) 0.88
Temporal trends in pulse pressure and mean arterial pressure during the rise of pediatric obesity in US children. J Am Heart Assoc (2014) 0.82
Effects of prior acute exercise on circulating cytokine concentration responses to a high-fat meal. Physiol Rep (2013) 0.81
Pulsatile and Steady-State Pressure Trends in Children: A Window into the Future? Pulse (Basel) (2015) 0.78
How to assess the link between vascular biology and arterial hemodynamics? Hypertension (2012) 0.75
Aortic Stiffness in Youth with Hypertrophic Cardiomyopathy Genotype. Pediatr Cardiol (2016) 0.75
Elevated Markers of Vascular Remodeling and Arterial Stiffness Are Associated with Neurocognitive Function in Older HIV+ Adults on Suppressive Antiretroviral Therapy. J Acquir Immune Defic Syndr (2016) 0.75
Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science (1997) 15.48
The biology of vascular endothelial growth factor. Endocr Rev (1997) 13.70
Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension (2001) 11.18
The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol (2007) 9.90
Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation (2010) 9.09
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem (1998) 8.30
Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension (2004) 8.27
Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation (2006) 8.18
Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation (2005) 6.89
Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res (1998) 3.79
Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction. Circ Res (2004) 2.50
Cross-sectional relations of peripheral microvascular function, cardiovascular disease risk factors, and aortic stiffness: the Framingham Heart Study. Circulation (2005) 2.49
Cross-sectional correlates of increased aortic stiffness in the community: the Framingham Heart Study. Circulation (2007) 2.42
Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol (2003) 2.26
Remodeling of blood vessels: responses of diameter and wall thickness to hemodynamic and metabolic stimuli. Hypertension (2005) 2.23
Haemodynamic basis for the development of left ventricular failure in systolic hypertension and for its logical therapy. J Hypertens (1995) 2.15
Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation (1995) 2.07
Hemodynamic correlates of blood pressure across the adult age spectrum: noninvasive evaluation in the Framingham Heart Study. Circulation (2010) 2.07
Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med (1987) 2.00
Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation (2002) 1.93
Cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function. Circulation (2006) 1.78
Effect of aging on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis. Comparison between occidental and Chinese communities. Am J Pathol (1991) 1.76
Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol (2001) 1.74
Arterial aging and subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levels. Med Clin North Am (2009) 1.59
Structural adaptation of microvascular networks: functional roles of adaptive responses. Am J Physiol Heart Circ Physiol (2001) 1.37
Adaptation of skeletal muscle microvasculature to increased or decreased blood flow: role of shear stress, nitric oxide and vascular endothelial growth factor. J Vasc Res (2009) 1.32
High pulsatility flow induces adhesion molecule and cytokine mRNA expression in distal pulmonary artery endothelial cells. Ann Biomed Eng (2009) 1.26
Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study. Circulation (2008) 1.26
Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab (2007) 1.16
Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol (2001) 1.15
Humoral and cellular factors responsible for coronary collateral formation. Am J Cardiol (2006) 1.14
Circulating insulin-like growth factor-1 and its binding protein-3: metabolic and genetic correlates in the community. Arterioscler Thromb Vasc Biol (2010) 1.11
Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function. Eur Heart J (2009) 1.10
Aging and arteriosclerosis. Cell cycle kinetics of young and old arterial smooth muscle cells. Am J Pathol (1988) 1.06
Insulin-like growth factor-I regulates transcription of the elastin gene. J Biol Chem (1993) 1.05
The effect of GH and IGF1 on linear growth and skeletal development and their modulation by SOCS proteins. J Endocrinol (2010) 1.04
A mechanism for arteriolar remodeling based on maintenance of smooth muscle cell activation. Am J Physiol Regul Integr Comp Physiol (2008) 1.02
Enhanced proliferation and migration and altered cytoskeletal proteins in early passage smooth muscle cells from young and old rat aortic explants. Exp Mol Pathol (1997) 1.02
Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens (2003) 1.00
Vascular endothelial growth factor and the angiopoietins: working together to build a better blood vessel. Circ Res (1998) 0.99
VEGF and angiopoietin-1 stimulate different angiogenic phenotypes that combine to enhance functional neovascularization in adult tissue. Microcirculation (2006) 0.99
A potential inverse association between insulin-like growth factor I and hypertension in a cross-sectional study. Ann Epidemiol (2006) 0.97
Arteriolar genesis and angiogenesis induced by endothelial nitric oxide synthase overexpression results in a mature vasculature. Arterioscler Thromb Vasc Biol (2008) 0.94
Interaction between pulse wave velocity, augmentation index, pulse pressure and left ventricular function in chronic heart failure. J Hum Hypertens (2006) 0.93
Vascular endothelial growth factor and soluble P-selectin in acute and chronic congestive heart failure. Am J Cardiol (2002) 0.92
Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects. J Hypertens (2009) 0.89
Clinical and genetic correlates of circulating angiopoietin-2 and soluble Tie-2 in the community. Circ Cardiovasc Genet (2010) 0.89
Hypertension and angiogenesis. Curr Pharm Des (2003) 0.88
Increased levels of insulin-like growth factor binding protein-3 in hypertensive patients with carotid atherosclerosis. Am J Hypertens (2003) 0.86
Interactive effects of insulin-like growth factor-1 and beta-estradiol on endothelial nitric oxide synthase activity in rat aortic endothelial cells. Metabolism (2003) 0.83
Single low-dose administration of human recombinant hepatocyte growth factor attenuates intimal hyperplasia in a balloon-injured rabbit iliac artery model. Circulation (2000) 0.81
Correlation between carotid artery distensibility and serum vascular endothelial growth factor concentrations in type 1 diabetic subjects and nondiabetic subjects. Metabolism (2001) 0.79
Decreased serum vascular endothelial growth factor concentrations in patients with congestive heart failure. Heart (2003) 0.79
Reduced nitric oxide levels in acromegaly: cardiovascular implications. Blood Press (2005) 0.77
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29
General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation (2008) 26.42
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 17.18
Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation (2007) 12.79
Obesity and the risk of heart failure. N Engl J Med (2002) 12.58
Metabolite profiles and the risk of developing diabetes. Nat Med (2011) 12.22
Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54
Long-term trends in the incidence of and survival with heart failure. N Engl J Med (2002) 10.37
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol (2007) 9.90
Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med (2008) 9.68
Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation (2010) 9.09
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 8.90
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 8.80
Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation (2002) 8.49
Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension (2004) 8.27
Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol (2003) 7.47
Predictors of new-onset kidney disease in a community-based population. JAMA (2004) 7.45
Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease. Circulation (2003) 7.40
Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet (2009) 7.27
Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med (2004) 7.12
Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA (2007) 6.95
Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA (2002) 6.84
Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation (2003) 6.83
Obesity and the risk of new-onset atrial fibrillation. JAMA (2004) 6.73
The clinical implications of endothelial dysfunction. J Am Coll Cardiol (2003) 6.71
A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet (2006) 6.39
Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation (2007) 6.34
Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med (2007) 6.29
Aortic stiffness, blood pressure progression, and incident hypertension. JAMA (2012) 6.01
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation (2006) 5.97
Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation (2008) 5.95
Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet (2008) 5.89
Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab (2006) 5.33
Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA (2009) 5.22
Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet (2009) 5.20
Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation (2007) 5.10
The Framingham Heart Study 100K SNP genome-wide association study resource: overview of 17 phenotype working group reports. BMC Med Genet (2007) 5.02
Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med (2004) 4.92
Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA (2004) 4.85
Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet (2009) 4.78
A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA (2003) 4.77
Trends in cardiovascular complications of diabetes. JAMA (2004) 4.74
Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation (2004) 4.73